Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
The first drug to treat Peyronie’s disease — an embarrassing and sometimes painful curvature of the penis — won approval on Friday from the Food and Drug Administration.
The drug, Xiaflex, is made by Auxilium Pharmaceuticals. It estimates as many as 9 percent of men have the condition, which can make intercourse painful or impossible.
Men with advanced prostate cancer survived significantly longer on a combination of two types of drugs than if they were started on the standard single treatment, according to a major federally sponsored study, which researchers suggested should change the way many such patients are treated.
The treatments involved hormone therapy to suppress levels of testosterone, the natural fuel for prostate tumors, and the chemotherapy docetaxel. Conventional practice has been to start men on testosterone suppression and then try docetaxel chemotherapy once the cancer progressed, said Christopher Sweeney, a medical oncologist at the Harvard-affiliated Dana-Farber Cancer Institute in Boston and lead investigator for the study.
But the 790-patient trial, which began in 2006, found that 69% of men who started with the combination therapy were alive after three years, compared with 52.5% who were started on hormone therapy alone, researchers said Thursday.
Study in the Journal Cell Cycle reveals new developments in prognosis
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. This sharp contrast between low-risk and aggressive disease presents a challenge for many researchers and physicians as they diagnose patients and also determine the prognosis of the men with the most aggressive forms of prostate cancer.
Researchers have discovered that the presence of a specific genetic mutation indicates a low likelihood of bladder cancer recurrence. STAG2 mutations have been observed in a number of cancers, but when Todd Waldman, MD, PhD, a cancer geneticist at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., and colleagues examined 2,214 human tumors from various body sites, they found that STAG2 was most commonly inactivated in bladder cancer. The investigators recorded truncating mutations of the STAG2 gene in 36% of the papillary noninvasive urothelial carcinomas and in 16% of the invasive urothelial carcinomas of the bladder.
The objective of this study was to examine the prognostic value of baseline health-related quality of life (HRQOL) for survival with regard to different cancer sites using 1 standardized and validated patient self-assessment tool.
The flowing movements and meditative exercises of the mind-body activity Qigong may help survivors of prostate cancer to combat fatigue. These are the findings of a trial study led by Dr. Anita Y. Kinney at the University of New Mexico Cancer Center and Dr. Rebecca Campo at the University of North Carolina at Chapel Hill. The study took place at the Huntsman Cancer Institute at the University of Utah, and was published in Springer’s Journal of Cancer Survivorship.
Despite concern about an increased risk for kidney stones with vitamin D supplementation, researchers have concluded that a serum 25-hydroxyvitamin D (25[OH]D) level of 20 to 100 ng/mL has no significant association with kidney stone incidence.
Among 2,012 individuals followed prospectively for a median of 19 months, 13 reported having developed a kidney stone during the study period. Although body mass index (BMI) was significantly associated with kidney stone risk (patients with a BMI of 30 or greater had a higher incidence rate of kidney stones than did others), the association between serum 25(OH)D and kidney stone development was not statistically significant.
As the population ages, more men are experiencing waning testosterone levels, which can contribute to depression and changes in blood pressure and blood sugar.
A new review, published in the Journal of Clinical Endocrinology & Metabolism (JCEM), of nine observational studies from 1970 to 2013, however, reveals that men with low testosterone may also have a slightly higher risk of developing or dying from heart disease compared to men with higher levels.
Specific genetic factors may be involved in the progression and differential tumor response in men with intermediate-risk prostate cancer who fail radiotherapy or radical prostatectomy (RP), new findings presented at the American Society for Radiation Oncology's 55th annual meeting suggest.
“There are some hot spots for mutations and gene alterations and basically it may be possible to tell the urologist which patients need intensified treatment beyond surgery or radiotherapy alone,” study investigator Alireza Fotouhi Ghiam, MD, a radiation oncology resident at the University of Toronto, told Renal & Urology News.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.